Intelectin-1
ITLN1geneITLN1 modulates innate immune responses and metabolic inflammation linked to atherosclerotic risk.
Pathway placement
Cascade stepPlaque inflammation
Confidencelow
RationaleObesity-related AMI marker; immune lectin involved in inflammatory homeostasis.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000179914
Type I vs non-Type I discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I23
C — non-Type-I46
A — assay feasibility52
E — evidence strength17
T1DI (composite)3
Specificity differential (R−C)-23.1
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable
Literature evidence(1)
- Deciphering the clinical implication of an obesity-related gene signature as the novel biomarker for acute myocardial infarction diagnosis.Scientific reports · 2025 · PMID 41461688 · doi